Praktiknjo M, et al. - In 73 non-obese human immunodeficiency virus (HIV)-monoinfected patients, researchers assessed fibroblast growth factor 21 (FGF-21) as a biomarker for severe hepatic steatosis. Data reported that severe hepatic steatosis prevalence was 41%. Severe hepatic steatosis patients showed significantly higher FGF-21 levels. This prospective, cross-sectional, monocentric study presents FGF-21 in patients infected with HIV as an independent and stronger predictor of severe hepatic steatosis vs blood lipids. In addition, even in non-obese HIV-monoinfected patients, arterial hypertension and ALT levels predict severe steatosis. This investigation also supports existing metabolic risk factors and expands them to non-obese patients with HIV infection.